SynthesisFrontiers in medicine2025
Diagnostic potential of salivary biomarkers for primary biliary cholangitis: a systematic review.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent studies have explored saliva as a non-invasive diagnostic fluid across various systemic and autoimmune conditions. However, its potential role in diagnosing primary biliary cholangitis (PBC) remains unclear. Aim: This systematic review examines whether salivary biomarkers can assist in the diagnosis of PBC. Materials and methods: Indexed databases (PubMed and Scopus) and bibliographies of relevant articles were searched between November 2024 and December 2024. Original cross-sectional studies investigating salivary biomarkers specifically for PBC diagnosis were included. Quality appraisal was conducted using the Joanna Briggs Institute (JBI) critical appraisal checklist. Results: Three studies involving 204 participants met the inclusion criteria. Salivary antimitochondrial antibodies-M2 (AMA-M2), pyruvate dehydrogenase complex E2 (PDC-E2) related autoantibodies, and inflammatory cytokines [interleukin (IL)-6, IL-17A, interferon gamma (IFN-γ), tumour necrosis factor alpha (TNF-α)] were consistently elevated in PBC patients compared with healthy controls. Proteomic alterations, particularly increased cystatin S-type proteins and altered S100A family proteoforms, also differentiated PBC from healthy groups. Among all markers, AMA-M2 and PDC-E2 specific antibodies demonstrated the highest diagnostic specificity. Conclusion: Available evidence suggests that select salivary autoantibodies and inflammatory proteins may hold diagnostic potential for PBC. Although promising, current data are limited, and larger, standardised studies are required to validate these biomarkers for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.